These findings highlight the intricate interplay between IL-17A, BBB integrity, and neuroinflammation in chronic migraines and suggest that targeting cytokine-mediated BBB disruption could offer novel therapeutic strategies for neuroimmune disorders beyond migraines, including multiple sclerosis and neuropsychiatric lupus erythematosus. This evidence concerns the gene IL17A and migraine disorder.